NCT00895674View on ClinicalTrials.gov

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

CompletedOBSERVATIONAL
Enrollment

2,840

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Carcinoma, Renal CellCarcinoma, Renal Cell (Advanced)
Interventions
DRUG

Nexavar (Sorafenib, BAY43-9006)

Patients with a diagnosis of advanced RCC

Trial Locations (18)

Unknown

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00895674 - Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar | Biotech Hunter | Biotech Hunter